TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06483178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune knee implant
Description: Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon knee implant
Description: Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
Study: NCT06134492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)
Study: NCT05772429

Intervention type: DRUG
Intervention: Epidiolex
Description: Administered as an oral solution
Study: NCT06274320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: holistic approach
Description: 2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Tolak® Standard of use
Description: 4-week Tolak® alone treatment (once daily in the evening)
Study: NCT05000281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg Ibuprofen 3 times a day for up to six weeks.
Study: NCT05719376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer (experimental)
Description: Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day

Intervention type: DRUG
Group type: OTHER
Intervention: control group
Description: Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
Study: NCT06558045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg film-coated tablet
Description: One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto 20 mg film-coated tablet
Description: One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
Study: NCT05749107

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm

Intervention type: COMBINATION_PRODUCT
Intervention: Proteomic analyses
Description: To identify the mechanisms leading to moderate/severe STR during AF.
Study: NCT06132516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LIGT
Description: Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
Study: NCT06246929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT+w
Description: MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ALED
Description: ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
Study: NCT06429488

Intervention type: OTHER
Intervention: no intervention, questionnaires were used
Description: The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD).

Intervention type: OTHER
Intervention: no intervention, questionnaires were used
Description: The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD).
Study: NCT06492889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
Study: NCT05505578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GamerFit Condition
Description: Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Condition
Description: Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
Study: NCT04857073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Monitoring
Description: Glucose monitoring consists of finger stick fasting and 2 hours post prandial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Monitoring
Description: Glucose monitoring consists of finger stick fasting and 2 hours post prandial
Study: NCT06492889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Participants in both groups will receive one tablet of 200 mg mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Participants in both groups will receive one tablet of 200 mg mifepristone
Study: NCT06100471

Intervention type: OTHER
Intervention: Observational study
Description: Observational study in different tissues in identifing new genetic markers related to endometriosis disease

Intervention type: OTHER
Intervention: Observational study
Description: Observational study in different tissues in identifing new genetic markers related to endometriosis disease

Intervention type: OTHER
Intervention: Observational study
Description: Observational study in different tissues in identifing new genetic markers related to endometriosis disease
Study: NCT05615168

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acumen IQ guided hemodynamic optimization
Description: Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Flotrac guided hemodynamic optimization
Description: Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor.
Study: NCT06036433

Intervention type: DEVICE
Group type: OTHER
Intervention: Infrared laser photobiomodulation device
Description: 904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared laser photobiomodulation device
Description: 904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.

Intervention type: DEVICE
Group type: OTHER
Intervention: Infrared & Red LED photobiomodulation device
Description: Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared & Red LED photobiomodulation device
Description: Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
Study: NCT05956886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep chatbot
Description: Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
Study: NCT05612659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical stimulation
Description: Noninvasive electrical stimulation of lateral frontal cortex.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous direct current stimulation
Description: Noninvasive electrical stimulation of the T10 spinal column.
Study: NCT02774694

Intervention type: DEVICE
Intervention: nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)
Description: measurement of the NFR threshold using the Paintracker device
Study: NCT05522699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cough suppressive therapy
Description: The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General healthy lifestyle instructions
Description: The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
Study: NCT05670951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELGN-2112
Description: Human insulin \[rDNA\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05257733

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: pure observationnal study

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: pure observationnal study
Study: NCT05711498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Description: tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Description: tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Description: tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
Study: NCT06316622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: measured by ultrasound
Study: NCT03785769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVGIC restoration with pre-etching
Description: Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVGIC restoration with non pre-etching
Description: Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
Study: NCT05676983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spiky balance disc
Description: Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric neurodevelopmental therapy
Description: Bobath therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric neurodevelopmental therapy
Description: Bobath therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smooth balance disc
Description: Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
Study: NCT04323462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Three times bolus insulin with regular or Shorter acting insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diabetic DM
Description: Previously receiving OADs and/or basal insulin
Study: NCT05367765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib
Description: Flumatinib 600mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 400mg orally daily (Reference drug instructions)
Study: NCT05867524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: 75g oral glucose tolerance test, sampled over three hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: 75g oral glucose tolerance test, sampled over three hours
Study: NCT06296498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Platelet-rich fibrin
Description: Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care OFD
Description: Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
Study: NCT05199870

Intervention type: DEVICE
Intervention: Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head
Description: Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head.
Study: NCT05840913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Description: Local anesthetic injection for intra- operative pain control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Description: Local anesthetic injection for intra- operative pain control
Study: NCT04722276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive end expiratory pressure
Description: 7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen 80%
Description: fraction of inspired oxygen 80% applied during induction of anesthesia
Study: NCT05244447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Services
Description: Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
Study: NCT05121727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep and Superficial Serratus Anterior Plane Block
Description: Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
Study: NCT05867524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling test
Description: 2 hours of moderate activity level cycling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling test
Description: 2 hours of moderate activity level cycling
Study: NCT05746377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg
Description: IV Metoclopramide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT04968106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide
Description: Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
Study: NCT05872464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial saliva containing cumin and ginger extract
Description: Artificial saliva containing cumin and ginger extract in spray bottle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
Study: NCT06307041

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental floss+Gengigel
Description: 0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental Floss
Description: Dental Flosses